Continuous erythropoiesis receptor activator (CERA)

Chronic kidney disease (CKD) affects 20 million Americans, and an additional 20 million are at increased risk for developing CKD. Anemia is a common complication in patients with CKD. The predominant cause of anemia in this patient population is a deficiency in erythropoietin. Continuous erythropoie...

Full description

Saved in:
Bibliographic Details
Published in:Formulary (Cleveland, Ohio) Ohio), 2007-04, Vol.42 (4), p.233
Main Authors: O'Mara, Neeta Bahal, Kapoian, Toros
Format: Article
Language:English
Subjects:
Anemia
Clinical trials
Creatinine
Hemodialysis
Hemoglobin
Kidney diseases
Medical research
Medical treatment
Mortality
Patient satisfaction
Prescription drugs
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 4
container_start_page 233
container_title Formulary (Cleveland, Ohio)
container_volume 42
creator O'Mara, Neeta Bahal
Kapoian, Toros
description Chronic kidney disease (CKD) affects 20 million Americans, and an additional 20 million are at increased risk for developing CKD. Anemia is a common complication in patients with CKD. The predominant cause of anemia in this patient population is a deficiency in erythropoietin. Continuous erythropoiesis receptor activator (CERA) is a new erythropoiesis-stimulating agent (ESA) that is undergoing FDA review for the treatment of anemia in patients with CKD, including in those undergoing dialysis. CERA has an extended half-life and a mechanism of action that promotes increased stimulation of erythropoietin receptors compared with other ESAs. In clinical trials, CERA dosed every 3 to 4 weeks has demonstrated efficacy similar to that of epoetin alfa and darbepoetin alfa in maintaining hemoglobin concentrations within the target hemoglobin range. CERA has generally been well tolerated in clinical trials. Further studies are needed to determine what the role of CERA will be in the hospital and outpatient settings. [PUBLICATION ABSTRACT]
format article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_229924549</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1271537241</sourcerecordid><originalsourceid>FETCH-proquest_journals_2299245493</originalsourceid><addsrcrecordid>eNpjYuA0tDS20DU0NDNjAbINLIx0LQwMIzgYuIqLswwMDMzMjI04GYyd8_NKMvNK80uLFVKLKksyivIL8jNTizOLFYpSk1MLSvKLFBKTSzLLEkEsDWfXIEdNHgbWtMSc4lReKM3NoOTmGuLsoVtQlF9YmlpcEp-VX1qUB5SKNzKytDQyMTWxNCZKEQDbczVv</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>229924549</pqid></control><display><type>article</type><title>Continuous erythropoiesis receptor activator (CERA)</title><source>Business Source Ultimate</source><creator>O'Mara, Neeta Bahal ; Kapoian, Toros</creator><creatorcontrib>O'Mara, Neeta Bahal ; Kapoian, Toros</creatorcontrib><description>Chronic kidney disease (CKD) affects 20 million Americans, and an additional 20 million are at increased risk for developing CKD. Anemia is a common complication in patients with CKD. The predominant cause of anemia in this patient population is a deficiency in erythropoietin. Continuous erythropoiesis receptor activator (CERA) is a new erythropoiesis-stimulating agent (ESA) that is undergoing FDA review for the treatment of anemia in patients with CKD, including in those undergoing dialysis. CERA has an extended half-life and a mechanism of action that promotes increased stimulation of erythropoietin receptors compared with other ESAs. In clinical trials, CERA dosed every 3 to 4 weeks has demonstrated efficacy similar to that of epoetin alfa and darbepoetin alfa in maintaining hemoglobin concentrations within the target hemoglobin range. CERA has generally been well tolerated in clinical trials. Further studies are needed to determine what the role of CERA will be in the hospital and outpatient settings. [PUBLICATION ABSTRACT]</description><identifier>ISSN: 1082-801X</identifier><identifier>EISSN: 1938-1166</identifier><language>eng</language><publisher>North Olmsted: MultiMedia Healthcare Inc</publisher><subject>Anemia ; Clinical trials ; Creatinine ; Hemodialysis ; Hemoglobin ; Kidney diseases ; Medical research ; Medical treatment ; Mortality ; Patient satisfaction ; Prescription drugs</subject><ispartof>Formulary (Cleveland, Ohio), 2007-04, Vol.42 (4), p.233</ispartof><rights>Copyright Advanstar Communications, Inc. Apr 2007</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids></links><search><creatorcontrib>O'Mara, Neeta Bahal</creatorcontrib><creatorcontrib>Kapoian, Toros</creatorcontrib><title>Continuous erythropoiesis receptor activator (CERA)</title><title>Formulary (Cleveland, Ohio)</title><description>Chronic kidney disease (CKD) affects 20 million Americans, and an additional 20 million are at increased risk for developing CKD. Anemia is a common complication in patients with CKD. The predominant cause of anemia in this patient population is a deficiency in erythropoietin. Continuous erythropoiesis receptor activator (CERA) is a new erythropoiesis-stimulating agent (ESA) that is undergoing FDA review for the treatment of anemia in patients with CKD, including in those undergoing dialysis. CERA has an extended half-life and a mechanism of action that promotes increased stimulation of erythropoietin receptors compared with other ESAs. In clinical trials, CERA dosed every 3 to 4 weeks has demonstrated efficacy similar to that of epoetin alfa and darbepoetin alfa in maintaining hemoglobin concentrations within the target hemoglobin range. CERA has generally been well tolerated in clinical trials. Further studies are needed to determine what the role of CERA will be in the hospital and outpatient settings. [PUBLICATION ABSTRACT]</description><subject>Anemia</subject><subject>Clinical trials</subject><subject>Creatinine</subject><subject>Hemodialysis</subject><subject>Hemoglobin</subject><subject>Kidney diseases</subject><subject>Medical research</subject><subject>Medical treatment</subject><subject>Mortality</subject><subject>Patient satisfaction</subject><subject>Prescription drugs</subject><issn>1082-801X</issn><issn>1938-1166</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><recordid>eNpjYuA0tDS20DU0NDNjAbINLIx0LQwMIzgYuIqLswwMDMzMjI04GYyd8_NKMvNK80uLFVKLKksyivIL8jNTizOLFYpSk1MLSvKLFBKTSzLLEkEsDWfXIEdNHgbWtMSc4lReKM3NoOTmGuLsoVtQlF9YmlpcEp-VX1qUB5SKNzKytDQyMTWxNCZKEQDbczVv</recordid><startdate>20070401</startdate><enddate>20070401</enddate><creator>O'Mara, Neeta Bahal</creator><creator>Kapoian, Toros</creator><general>MultiMedia Healthcare Inc</general><scope>3V.</scope><scope>7RV</scope><scope>7WY</scope><scope>7X7</scope><scope>7XB</scope><scope>883</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FL</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FRNLG</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K60</scope><scope>K6~</scope><scope>K9.</scope><scope>KB0</scope><scope>L.-</scope><scope>M0F</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PADUT</scope><scope>PQBIZ</scope><scope>PQBZA</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PYYUZ</scope><scope>Q9U</scope><scope>S0X</scope></search><sort><creationdate>20070401</creationdate><title>Continuous erythropoiesis receptor activator (CERA)</title><author>O'Mara, Neeta Bahal ; Kapoian, Toros</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_2299245493</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Anemia</topic><topic>Clinical trials</topic><topic>Creatinine</topic><topic>Hemodialysis</topic><topic>Hemoglobin</topic><topic>Kidney diseases</topic><topic>Medical research</topic><topic>Medical treatment</topic><topic>Mortality</topic><topic>Patient satisfaction</topic><topic>Prescription drugs</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>O'Mara, Neeta Bahal</creatorcontrib><creatorcontrib>Kapoian, Toros</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing &amp; Allied Health Database</collection><collection>ABI/INFORM Collection</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ABI/INFORM Trade &amp; Industry (Alumni Edition)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection (Alumni Edition)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Business Premium Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Business Premium Collection (Alumni)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Business Collection (Alumni Edition)</collection><collection>ProQuest Business Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ABI/INFORM Professional Advanced</collection><collection>ABI/INFORM Trade &amp; Industry</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest Health Management Database</collection><collection>Medical Database</collection><collection>ProQuest Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Research Library China</collection><collection>One Business</collection><collection>ProQuest One Business (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ABI/INFORM Collection China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><jtitle>Formulary (Cleveland, Ohio)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>O'Mara, Neeta Bahal</au><au>Kapoian, Toros</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Continuous erythropoiesis receptor activator (CERA)</atitle><jtitle>Formulary (Cleveland, Ohio)</jtitle><date>2007-04-01</date><risdate>2007</risdate><volume>42</volume><issue>4</issue><spage>233</spage><pages>233-</pages><issn>1082-801X</issn><eissn>1938-1166</eissn><abstract>Chronic kidney disease (CKD) affects 20 million Americans, and an additional 20 million are at increased risk for developing CKD. Anemia is a common complication in patients with CKD. The predominant cause of anemia in this patient population is a deficiency in erythropoietin. Continuous erythropoiesis receptor activator (CERA) is a new erythropoiesis-stimulating agent (ESA) that is undergoing FDA review for the treatment of anemia in patients with CKD, including in those undergoing dialysis. CERA has an extended half-life and a mechanism of action that promotes increased stimulation of erythropoietin receptors compared with other ESAs. In clinical trials, CERA dosed every 3 to 4 weeks has demonstrated efficacy similar to that of epoetin alfa and darbepoetin alfa in maintaining hemoglobin concentrations within the target hemoglobin range. CERA has generally been well tolerated in clinical trials. Further studies are needed to determine what the role of CERA will be in the hospital and outpatient settings. [PUBLICATION ABSTRACT]</abstract><cop>North Olmsted</cop><pub>MultiMedia Healthcare Inc</pub></addata></record>
fulltext fulltext
identifier ISSN: 1082-801X
ispartof Formulary (Cleveland, Ohio), 2007-04, Vol.42 (4), p.233
issn 1082-801X
1938-1166
language eng
recordid cdi_proquest_journals_229924549
source Business Source Ultimate
subjects Anemia
Clinical trials
Creatinine
Hemodialysis
Hemoglobin
Kidney diseases
Medical research
Medical treatment
Mortality
Patient satisfaction
Prescription drugs
title Continuous erythropoiesis receptor activator (CERA)
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T00%3A56%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Continuous%20erythropoiesis%20receptor%20activator%20(CERA)&rft.jtitle=Formulary%20(Cleveland,%20Ohio)&rft.au=O'Mara,%20Neeta%20Bahal&rft.date=2007-04-01&rft.volume=42&rft.issue=4&rft.spage=233&rft.pages=233-&rft.issn=1082-801X&rft.eissn=1938-1166&rft_id=info:doi/&rft_dat=%3Cproquest%3E1271537241%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-proquest_journals_2299245493%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=229924549&rft_id=info:pmid/&rfr_iscdi=true